Ninlaro Prolongs Progression-free Survival in Multiple Myeloma Patients Not Given ASCT, Phase 3 Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) prolongs…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows
Adding the lymphoma therapy vorinostat to Revlimid…
CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests
A new approach using genetically modified T-cells — via…
Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma
Nektar Therapeutics is launching a…
Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces
The U.S. Food and Drug Administration (FDA) has granted…
Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows
U.S. blood cancer specialists are aware of recent approvals…
